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49 
SUMMARY 50 
 51 
What is known and objective:  The CFTR potentiator, Ivacaftor (IVA), has been widely used in the 52 
treatment of cystic fibrosis (CF) patients with the G551D mutation.  To date, there has been limited 53 
information on the microbiological status of patients on this therapy and no data on the effect (if any) 54 
on the in vivo antibiotic susceptibility of Pseudomonas aeruginosa isolated from patients on therapy.  55 
Whilst IVA intervention is not designed per se as anti-infective, the effect (if any) of this molecule to 56 
CF patients’ microbiological status merits careful monitoring.  Therefore, it was the aim of this 57 
observational study to examine the effect in patients, both before and after commencement of IVA 58 
therapy, on several commonly reported microbiological markers in CF patients, including (i) bacterial 59 
density, (ii) frequency (rate) of isolation of bacterial pathogens, particularly Pseudomonas aeruginosa 60 
and (iii) antimicrobial susceptibility of these isolates to commonly prescribed oral and iv antibiotics.  61 
In addition, we wished to examine the requirements for these antibiotics in CF patients, before and 62 
after commencement of IVA therapy. 63 
 64 
Methods:  Archived data from 15 adult patients with the c.1652G›A  (G551D) mutation were followed 65 
from two years pre-IVA therapy to two years after commencement of IVA therapy.  The 66 
microbiological parameters examined included (i) oral antibiotic courses taken, (ii) intravenous (iv) 67 
antibiotic courses taken, (iii) rate of isolation of non-mucoid Pseudomonas aeruginosa (NM-PA) and 68 
mucoid Pseudomonas aeruginosa (M-PA), (iv) density of NM-PA and M-PA and (v) antimicrobial 69 
susceptibility of NM-PA and M-PA to 11 antibiotics [aminoglycosides, beta-lactams, polymyxin and 70 
fluoroquinolone] 71 
 72 
Results and discussion:  Following commencement of IVA therapy, patients required less iv antibiotic 73 
courses but no change in number of oral antibiotics courses.  There was significant reduction in both 74 
the rate of isolation and density of M-PA (p=0.02; p=0.006, respectively). In contrast, there was no 75 
significant reduction in both the rate of isolation and density of NM-PA (p=0.90; p=0.07, respectively).  76 
Antimicrobial susceptibility in NM-PA and M-PA was not significantly reduced within any of the 77 
antibiotics classes or individual antibiotics examined.  Increased susceptibility was noted in the 78 
beta-lactam class for NM-PA and M-PA, in particular with ceftazidime. 79 
 80 
What is new and conclusion:  Overall, (i) the requirement for less iv antibiotic therapy, (ii) a reduction 81 
in the rate and density of M-PA, and (iii) no reduction in antibiotic susceptibility, indicates that 82 
microbiological parameters with patients on IVA therapy were not detrimentally affected.  83 
 84 
 85 
 86 
  87 
What is known and objective:   88 
The dominant feature of cystic fibrosis (CF)-related disease is the deterioration in patients’ lung 89 
function due to the chronic presence of bacterial pathogens, particularly Pseudomonas aeruginosa.  90 
Any change in the status of the patient’s microbiology may have a significant effect in clinical 91 
outcome, in either a positive or negative manner. Outside of pulmonary exacerbation, the relative 92 
microbiological stability of the cystic fibrosis (CF) lung is a fine equilibrium of multiple factors.  In 93 
microbiological terms, these include the presence/absence of bacterial pathogens, numbers of 94 
organisms present, antibiotic resistance, carriage/expression of bacterial virulence determinants, 95 
relative phase of bacterial growth (e.g. presence of senescent cells/persisters), host/environmental 96 
stress responses and relative nutritional/starvation status of bacterial pathogens, iron sequestration and 97 
competition and the dynamic flux from the co-habiting microbiome of the lung.  Several other host 98 
(patient) related factors can also contribute to this instability in this two host [patient & bacterium] 99 
system. 100 
 101 
In microbiological terms, what is not well understood is the sequencing and interactions of these 102 
factors, when they occur together in a particular pattern, what precipitates the tipping of the relatively 103 
stable CF lung into a pulmonary exacerbation or alternatively the interactions which drive the CF lung 104 
to a more stable situation, thereby reducing infection and exacerbations.  In addition, the relative 105 
contribution and interaction of the human host undoubtedly plays a significant part in driving this 106 
stable equilibrium to a state of relative instability and hence onwards to a potential pulmonary 107 
exacerbation. 108 
 109 
The 21st century is witnessing the development of many new pharmacological interventions in CF, in 110 
order to ameliorate the effects of cystic fibrosis transmembrane conductance regulator (CFTR) 111 
dysfunction and thus improve patient outcomes.  One such intervention is the use of CFTR 112 
correctors/potentiators, as an effective intervention, which has revolutionized CF care in those patients 113 
with a genetic profile of their alleles which are predicted to benefit from such interventions.1  114 
Ivacaftor [N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide] 115 
(VX-770; Kalydeco®) [IVA] is an orally bioavailable CFTR-potentiator molecule,  that is designed to 116 
increase the time that activated CFTR channels at the cell surface remain open, in CF patients with 117 
specific mutations, including G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or 118 
S549R.  IVA therapy with genetically appropriate CF patients has been shown to improve lung 119 
function, as well as improve(i)  risk of pulmonary exacerbations,(ii)  patient-reported respiratory 120 
symptoms, (iii) weight, (iv) concentration of sweat chloride [1] and (v) quality of life.2 121 
 122 
Whilst IVA intervention is not designed per se as anti-infective, the effect (if any) of this molecule to 123 
CF patients’ microbiological status merits careful monitoring.  Therefore, it was the aim of this study to 124 
examine the effect in patients, both before and after commencement of IVA therapy, on several 125 
commonly reported microbiological markers in CF patients, including (i) bacterial density, (ii) 126 
frequency (rate) of isolation of bacterial pathogens, particularly Pseudomonas aeruginosa and (iii) 127 
antimicrobial susceptibility of these isolates to commonly prescribed oral and iv antibiotics.  In 128 
addition, we wished to examine the requirements for these antibiotics in CF patients, before and after 129 
commencement of IVA therapy. 130 
 131 
 132 
 133 
134 
Materials and methods 135 
 136 
Patient population 137 
A retrospective analysis was conducted on 15 adult patients, who were receiving therapeutic 138 
treatment for their cystic fibrosis with oral ivacaftor.  Each patient had a confirmed diagnosis of cystic 139 
fibrosis, with at least one copy of the G551D mutation.  Patients had an age range of 16-43 years and 140 
there were nine males (age range: 16 – 43years) and seven females (age range: 18-32 years).  Male 141 
patients treatment duration ranged from 18-30 months, with a mean treatment duration of 24 months 142 
and female patients treatment durations ranged from 18-29 months, with a mean treatment duration of 143 
23.4 months. 144 
 145 
Antibiotic treatment and microbiological parameters analysed 146 
Each parameter was examined (i) two years prior to commencement of ivacaftor therapy and (ii). two 147 
years post ivacaftor therapy.   148 
 149 
Archived microbiological data was analysed from the patients’ clinical microbiology record file, with 150 
particular reference to (i). total Pseudomonas aeruginosa (PA), (ii). non-mucoid (NM) PA and (iii). 151 
Mucoid (M) PA.  The specific microbiological parameters investigated included (i). incidence of (PA 152 
or NM PA or M PA)/respiratory specimen, (ii). relative culture density of PA [NM PA or M 153 
PA ]/respiratory specimen, (iii). antibiotic susceptibility.   154 
 155 
The rate of isolation of PA was defined as frequency of PA isolated from sputum and was presented as 156 
rate/respiratory specimen.  The density of PA isolated from respiratory specimen was quantitatively 157 
recorded by taking the laboratory semi-quantitative result (i.e. none, +, ++, +++) and converting these 158 
values into a fully quantitative value, ranging from 0, 1, 2 and 3, respectively, and expressed per 159 
respiratory specimen. 160 
 161 
Antibiotic susceptibility was defined by employment of the Relative Resistance Index (RRI)3 of PA 162 
isolates, within the following classes of antibiotics (agents analysed):  aminoglycosides (gentamicin, 163 
tobramycin, amikacin); -lactams (temocillin, ceftazidime, piperacillin/tazobactam, aztreonam), 164 
carbapenems (imipenem, meropenem), polymyxin (colistin) and fluoroquinolone (ciprofloxacin).  165 
Relative Resistance Index (RRI) values were calculated for each NM-PA and M-PA isolate in each 166 
patient, at each visit to the CF Unit, as either an in-patient or out-patient.  Antibiotic susceptibility was 167 
routinely recorded as sensitive (S), intermediate (M) or resistant (R).  Subsequently, for the purposes 168 
of this analysis, RRI values were assigned, as follows:  a value of 1 for sensitivity, 2 is 169 
intermediate/moderate resistance and 3 for resistant. 170 
 171 
Additionally, the number of antibiotic courses, both oral and intravenous (IV), were analysed and 172 
expressed as the mean courses of antibiotics given per month over the two years prior to 173 
commencement of ivacaftor therapy and the two years after commencement of ivacaftor therapy.  174 
 175 
Statistical analysis 176 
Student t-tests were used to compare pre-ivacaftor and post-ivacaftor microbiology findings.  Where 177 
unpaired t-tests were employed, F values were calculated to determine equal or unequal variance.  P 178 
values and confidence intervals (CIs) were two-sided, where p≤0.05 (5%) was deemed significant. 179 
Error bars were calculated as ± standard error of the mean (SEM). 180 
 181 
182 
Results 183 
 184 
Antibiotic therapy 185 
There was no significant difference between the number of oral antibiotic courses/month before and 186 
after IVA therapy (0.1 v 0.07; p=0.41) (Figure 1).  There was a significant reduction in the number of 187 
iv antibiotic courses/month, following IVA therapy (0.15 v 0.02; p=0.0003) (Figure 2).  There was no 188 
requirement for iv antibiotics in 6/15 (40%) patients, both prior to and following commencement of 189 
IVA therapy.  Five of the patients who required iv antibiotics pre-IVA therapy (33.3%) subsequently 190 
did not require iv antibiotics, following commencement of IVA therapy.  For the remainder of the 191 
patients, 4/15 (26.7%) required less courses of iv antibiotics following commencement of IVA 192 
therapy. 193 
 194 
All patients who were taking nebulized anti-pseudomonal antibiotics for suppressive therapy 195 
continued to take these after commencement of IVA therapy and thus there was no change in the rate 196 
of inhaled antibiotics with the Pseudomonas-positive patients. 197 
 198 
Rate & density of Pseudomonas aeruginosa isolation from respiratory specimens 199 
 200 
Non-mucoid Pseudomonas aeruginosa 201 
Eleven patients from the total 15 patients included in this study were culture-positive for NM-PA, 202 
prior to commencement of IVA therapy.  Overall at a population level, there was no significant 203 
difference in either the rate (p=0.90) or density (p=0.07) of NM-PA, following commencement of IVA 204 
therapy (Table 1).  When examined statistically, at individual patient level, the density of NM-PA was 205 
significantly lower (before v after commencement IVA therapy) in one patient (p=0.02), even though 206 
this patient had a constant rate of NM-PA isolation (Figure 3).  One patient acquired an NM-PA after 207 
commencement of IVA therapy, but this isolate appeared to be transient, as it was only reported in a 208 
single specimen, whereby the remaining six specimens were negative (data not shown). The other 209 
three patients remained NM-PA free.  210 
 211 
Mucoid Pseudomonas aeruginosa 212 
Nine patients in this study were culture-positive for M-PA, prior to commencement of IVA therapy.  213 
Overall, at a population level, there was a significant lowering in both the rate (p=0.02) and density 214 
(p=0.006) of M-PA, following commencement of IVA therapy (Table 1 & Figure 4).  Interestingly, a 215 
reduced density of M-PA isolation was statistically observed in three of the nine patients (33.3%) and 216 
additionally two patients became negative for M-PA after commencement of IVA therapy.  None of 217 
the six patients previously negative for M-PA prior to IVA therapy gained M-PA, after 218 
commencement of therapy.   219 
 220 
Other microorganisms 221 
There was no significant difference in both the rate (p=0.37) and density (p=0.43) of Staphylococcus 222 
aureus in patients (n=7), before v after commencement of IVA therapy.  Additionally, in one patient, 223 
there was no significant difference in the rate or density of Burkholderia cenocepacia, before v after 224 
commencement of IVA therapy.  For other non-Pseudomonas organisms, Table 2 details a qualitative 225 
comparison of microorganisms cultured in patients before and after commencement of IVA therapy. 226 
 227 
Antibiotic susceptibility in PA isolates 228 
The Relative Resistance Index [RRI]3 was employed as a semi-quantitative method to determine the 229 
susceptibility of NM-PA and M-PA.  In total, 366 isolates of PA were analysed for antibiotic 230 
susceptibility against 11 antibiotics, including 220 NM-PA (n=109 & n=111 before and after 231 
commencement of IVA therapy, respectively), as well as 146 M-PA (n=77 & n=69 before and after 232 
commencement of IVA therapy, respectively).  This equated to approximately 9-10 PA isolates per 233 
patient before, as well as after commencement of IVA therapy. 234 
 235 
Figure 5a shows antibiotic susceptibility, as expressed as RRI, for total PA (NM-PA + M-PA) against 236 
11 antibiotics within four antibiotic classes.  Figure 5b shows antibiotic susceptibility, as expressed as 237 
RRI, for NM-PA and Figure 5c for M-PA. 238 
 239 
There were no statistically significant differences in antibiotic susceptibility for the aminoglycosides, 240 
polymyxin (colistin) or fluoroquinolone (ciprofloxacin) in NM-PA and M-PA (Figure 5a-c).  Whilst 241 
Figure 5a-c shows a general lowering of the RRI value, this was only statistically significant in one 242 
class of antibiotics, namely certain -lactam antibiotics, before and after commencement of IVA 243 
therapy.  For total PA, there is a significant increase in susceptibility relating to ceftazidime 244 
(p=0.002), tazocin (p=0.004), azteonam (p=0.045) and meropenem (p=0.005).  Regarding NM-PA, 245 
three -lactams showed a significant increase in susceptibility, namely ceftazidime (p=0.03), tazocin 246 
(p=0.002) and meropenem (p=0.02), whilst only ceftazidime showed a significant increase in 247 
susceptibility (p=0.04), with M-PA (see Figure 5a-c). 248 
 249 
 250 
  251 
Discussion 252 
 253 
With any novel non-antimicrobial pharmacological intervention in CF, it is important to carefully 254 
monitor the microbiological status of patients on therapy, in order to ensure that the intervention is not 255 
having a deleterious effect on the patients’ microbiological parameters, which could potentially 256 
manifest in clinical deterioration.  In this observational study, our objective was to retrospectively 257 
examine the microbiology of CF patients, who had received IVA therapy.  This was achieved by 258 
examining microbiological data routinely gathered as part of the patient CF care pathway, from two 259 
years proceeding initiation of IVA therapy and continuing to approximately two years after 260 
commencement of IVA. 261 
 262 
Overall, there was a significant reduction in the requirement for iv antibiotic courses when patients 263 
commenced IVA therapy (p= 0.0003) (Figure 2).  Of the nine patients who required iv antibiotics, 264 
prior to the commencement of IVA therapy, five of these did not require any iv antibiotics, whilst on 265 
IVA therapy and the remaining four patients required a reduced number of iv antibiotic courses.  We 266 
did not observe any patient, who did not routinely receive iv antibiotics subsequently requiring iv 267 
antibiotics whilst on IVA therapy.  268 
 269 
In contrast, there was no statistical difference in requirement for oral antibiotics before versus after 270 
commencement of IVA therapy (p=0.41).  Nine patients from the 15 patients examined in this study 271 
required oral antibiotics, prior to commencement of IVA therapy and seven of these patients 272 
continued to require oral antibiotics whilst on IVA therapy.  Following commencement of therapy, 273 
there were two patients who did not require any oral antibiotics and one patient who did require oral 274 
antibiotics on therapy, who did not require oral antibiotics before commencement of IVA.   275 
 276 
Similarly, in a recent study from the Czech Republic, a 21% reduction on antibiotic therapy (per 277 
patient-year) was reported (p<0.001), however it is not clear whether this therapy included oral, ivs or 278 
both.4  In our study we observed an overall significant reduction (86.7%) in the number of iv 279 
antibiotic courses per month and a 20% reduction in the number of oral antibiotic courses per month, 280 
although not statistically significant. 281 
 282 
The question does however remain from our study, as to why iv antibiotic usage went down, whilst 283 
oral usage remained unaltered.  One possible explanation is a lower clinical threshold for starting an 284 
oral antibiotic in healthier patients versus that for commencement of an iv antibiotic in sicker patients. 285 
Consequently, oral antibiotics may be an interesting first choice for examining antimicrobial 286 
stewardship within cystic fibrosis. 287 
 288 
There was no significance difference in either the rate of isolation or density of NM-PA after 289 
commencement of IVA therapy. This was in contrast to M-PA, where there was a significant reduction 290 
in both the rate of isolation and density. To date, there have been no other reports which have divided 291 
total PA into NM-PA and M-PA components, however the study by Heltshe et al. reported significant 292 
reduction in the percentage of patients with total PA (p=0.004) and M-PA (p=0.05), following 1 year 293 
post IVA therapy.5  More recently, a further study reported that IVA caused a marked reduction in PA 294 
density, which commenced 48 hours post commencement of IVA therapy and which continued in the 295 
first year of therapy. Following this, PA density rebounded in 6/7 patients, commencing at day 210 on 296 
IVA therapy.6 297 
 298 
There is a relative paucity of data describing the fate of bacterial numbers in patients commencing 299 
IVA therapy.  Recently published data  from the 2013 NACFC Meeting demonstrated that appropriate 300 
patients on ivacaftor had improved mucociliary clearance7 and demonstrated that mucociliary 301 
clearance increased from 8.5 ± 1.7% at baseline to 18.7 ± 2.3% and 17.7 ± 1.7% at one and three 302 
months post-treatment, respectively (p < 0.001 for each comparison to baseline). Dramatic 303 
improvements in peripheral lung clearance were also demonstrated (1.5 ± 1.8% vs.12.2 ±  2.0%, 9.1 ± 304 
2.4% at baseline, one month and three months, respectively; p < 0.05 for each comparison to baseline. 305 
Current research, which is part of the GOAL observational study, from Sagel’s group in Colorado, 306 
also presented at the recent NACFC meeting.8  Induced sputum was collected pre- and post-ivacaftor 307 
treatment in 14 subjects (age 27 ± 14 yrs; FEV1 84 ± 23% predicted; 6 females).  Sputum bacterial 308 
diversity did not change significantly with treatment [Shannon Diversity: mean change (SE) 0.13 309 
(0.14), p=0.34]. The combined relative abundance (RA) of traditional CF bacterial pathogens 310 
including Pseudomonas, Staphylococcus, Stenotrophomonas, Achromobacter, and Burkholderia 311 
trended down with treatment [mean change (SE) -13.9 (8.2), p=0.11]. Prevotella RA significantly 312 
increased with treatment [mean change (SE) 8.8 (3.0), p=0.01]. By qPCR, neither total bacterial load 313 
changed significantly between paired samples [mean change (SE) −0.18 (0.16) log10 gene 314 
copies/mL, p=0.28], nor did Pseudomonas load [mean change (SE) −0.76 (0.66) log10 gene 315 
copies/mL, p=0.27]. There were no significant changes in any sputum markers of inflammation, 316 
including neutrophil elastase activity [mean change (SE) -0.1 (0.1) log10 μg/mL, p=0.29]. 317 
 318 
On first examination of the Sagel’s data,8 it would appear that nothing significant happened to the 319 
total bacterial counts nor the PA counts, which is counter- intuitive to data of Donaldson,7  with 320 
improved mucocillary clearance in patients on ivacaftor.  The problem here is that the Sagel group 321 
measured bacterial numbers with an inappropriate methodology, namely enumeration solely via a 322 
molecular means qPCR.  Where DNA is the target for qPCR determination, it will count total bacteria 323 
in the sputum specimen and consequently this will include both living, as well as dead bacterial cells.  324 
Given the persistence of DNA from living or dead bacterial cells, therefore any changes  (+ or -) in 325 
culturable bacterial numbers would be effectively missed by using this methodology.  The 326 
consequences of this would thus create an uncertainty as to whether or not the culturable bacteria in 327 
CF sputum in patients on ivacaftor remained constant or not.   328 
 329 
On considering the dynamics of growth of bacteria and bacterial CF respiratory pathogens in the CF 330 
airways in patients on ivacaftor, the published data regarding bacterial numbers counted either via 331 
molecularly6,8 or conventionally-acquired6 does not give any indication if such numbers are present 332 
due to (i) bacterial cells being in the stationery phase in a relative state of senescence/dormancy but 333 
which remain culturable, (ii). actively metabolising where numbers dying off equals numbers being 334 
generated de novo and (iii). have switched phenotypically from culturable sessile & planktonic 335 
vegetative cells to non-culturable persister cells.  Scenarios (i) and (ii) would show no significant 336 
change in numbers, even though the physiology leading to this point is completely different.  In this 337 
regard, due to the now functional ciliated escalator, bacteria need to work extremely hard to maintain 338 
their numbers constant, i.e. the Red Queen Hypothesis, as per the data of Sagel.8 339 
 340 
The consequences of which modality is happening is profound.  In the case of (i) above, bacterial 341 
cells are not actively dividing nor dying, therefore they will not have a high metabolic turnover and 342 
should not be as visible to the host immune system.  However, in the case of (ii) above, whilst there 343 
does not appear to be much happening, in terms of changes in bacterial counts, there is an important 344 
occult metabolism taking place, which would be very visible to the host’s immune system, which 345 
would drive inflammatory processes.  Therefore, it is import to understand the microbiological 346 
mechanisms underpinning the fate of constant bacterial populations within the CF airways in patients 347 
on IVA. 348 
 349 
To date, there have been no reports on the effect of IVA therapy on antibiotic susceptibility in PA.  In 350 
our study, overall, there was no decrease in antibiotic susceptibility observed in PA (NM-PA and 351 
M-PA) in this study.  Four classes of commonly employed antibiotics were examined, namely 352 
aminoglycosides, -lactams, a polymyxin and a fluoroquinolone.  There was no difference in 353 
susceptibility with the aminoglycoside, the polymyxin or the fluoroquinolone.  It was interesting to 354 
note the increase in susceptibility with the -lactam class of antibiotics, in particular ceftazidime, 355 
tazocin, aztreonam and meropenem.  A rationale for observing a signal in only the -lactam 356 
antibiotics remains uncertain and this is the subject of a further study, which is underway. 357 
 358 
Whilst our study reports statistical increase with certain antibiotic susceptibilities in PA, these values 359 
are largely of academic interest only.  These data did not demonstrate marked shifts in susceptibility 360 
which altered the susceptibility designation, from sensitive, intermediate or resistant.  Given this, IVA 361 
therapy should not construed in any manner in the antibiotic management of CF patients.  362 
Importantly, antibiotic susceptibility from patients on IVA therapy is not reduced and therefore IVA 363 
therapy does not appear to have a detrimental association with antimicrobial therapy. 364 
 365 
What is new and conclusions 366 
Overall, although the findings of this study cannot directly correlate with the effect of IVA therapy 367 
with microbiological parameters, it is of interest to note that microbiological parameters with patients 368 
on IVA therapy were not detrimentally affected. Indeed, overall, (i) the requirement for less iv 369 
antibiotic therapy, (ii) a reduction in the rate and density of M-PA, and (iii) no reduction in antibiotic 370 
susceptibility, suggests an improvement in the microbiology status of patients on IVA therapy.   371 
 372 
 373 
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Figure 1: Number of oral antibiotic course per month for patients before and after 420 
commencement of IVA therapy 421 
 422 
Figure 2: Number of intravenous antibiotic course per month for patients before and after 423 
commencement of IVA therapy 424 
 425 
Figure 3a: Rate of non-mucoid PA isolation before and after commencement of ivacaftor (IVA) 426 
therapy in patients who were chronically colonised prior to the commencement of IVA 427 
therapy 428 
 429 
Figure 3b: Density of non-mucoid PA isolation before and after commencement of ivacaftor  430 
(IVA) therapy in patients who were chronically colonised prior to the commencement 431 
of IVA therapy 432 
 433 
Figure 4a: Rate of mucoid PA isolation before and after commencement of ivacaftor (IVA) 434 
therapy in patients who were chronically colonised prior to the commencement of IVA 435 
therapy 436 
 437 
Figure 4b: Density of mucoid PA isolation before and after commencement of ivacaftor (IVA)  438 
therapy in patients who were chronically colonised prior to the commencement of IVA 439 
therapy 440 
 441 
Figure 5: Antibiotic susceptibility, as expressed by Relative Resistance Index, against four 442 
classes of antibiotic in (a) Total Pseudomonas aeruginosa, (b) Non-mucoid P. 443 
aeruginosa and (c) Mucoid P. aeruginosa, isolated from patients before and after 444 
commencement of ivacaftor therapy. 445 
(Abbreviations: IVA= ivacaftor; M= mucoid; NM= non-mucoid; PA= Pseudomonas aeruginosa) 446 
Table 1: Comparison of the rate of isolation and density of non-mucoid and mucoid 447 
Pseudomonas aeruginosa before and after commencement of ivacaftor therapy. 448 
 449 
Table 2: Non-Pseudomonas organisms cultured from CF patients’ respiratory specimens 450 
before and after commencement of ivacaftor therapy 451 
 452 
